Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peretinoin (K-333) for prevention of recurrence in HBV-positive hepatocellular carcinoma after curative treatment
jRCT2080222099Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Jun 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) and hepatitis B (HBV) comparing Peretinoin arm with Placebo arm (2 arms). Started Jun 2013; status: completed.
02
Drugs
peretinoin
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on jRCT2080222099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222099.